Skip to main content

Table 1 Baseline patient characteristics

From: Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy

  PSA progression during initial HT (n=27) Patient population without PSA progression (n=305)
patient age/years median (range) mean±SD 74 (45–81) 72±8 71 (52–84) 71±6
follow-up period/months† median (range) mean±SD 48 (11–113) 50±23 69 (2–115) 66±18
T stage >2a† 74% 25%
Gleason score >6† 48% 19%
primary PSA /ng/ml† median (range) mean±SD 16(4–150) 31±37 10(1–300) 16±25
low risk patients* 7% 37%
intermediate risk patients** 7% 28%
high risk patients*** 85% 35%
initial HT (before RT)† 100% 40%
initial HT >6months† 78% 13%
HDR-BT 19% 22%
EBRT 81% 78%
  1. * no risk factors: PSA<10ng/ml; Gleason score<7; cT-stage<2b.
  2. ** one risk factor: PSA 10-20ng/ml or Gleason score=7 or cT-stage=2b/c.
  3. *** two risk facors or PSA>20ng/ml or Gleason score>7 or cT-stage>2b/c.
  4. †statistically significant difference (p<0.01).
  5. Abbreviations: HDR-BT = high-dose rate brachytherapy; EBRT = external beam radiotherapy; SD = standard deviation; PSA = prostate-specific antigen; HT = hormonal therapy.